Quadrivalent Ann Arbor strain live-attenuated influenza vaccine. (November 2012)

• Record Type: Journal Article
• Authors: Toback, Seth L; Levin, Myron J; Block, Stan L; Belshe, Robert B; Ambrose, Christopher S; Falloon, Judith
• Is Part Of: Expert review of vaccines. Volume 11:Number 11(2012)
• Page Start: 1293
• Page End: 1303
• Publication Date: 2012-11
• Subjects: adults -- children -- clinical trials -- immunogenicity -- influenza B -- intranasal -- quadrivalent live-attenuated influenza vaccine -- safety; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/erv.12.108
• Languages: English
• ISSNs: 1476-0584

Abstract

Influenza B is responsible for significant morbidity in children and adults worldwide. For more than 25 years, two antigenically distinct lineages of influenza B viruses, B/Yamagata and B/Victoria, have cocirculated globally. Current influenza vaccine formulations are trivalent and contain two influenza subtype A strains (A/H1N1 and A/H3N2) but only one B strain. In a half of recent influenza seasons, the predominant circulating influenza B lineage was different from that contained in trivalent influenza vaccines. A quadrivalent live-attenuated influenza vaccine (Q/LAIV) that contains two B strains, one from each lineage, has been developed to help provide broad protection against influenza B. Q/LAIV was recently approved for use in the USA in eligible individuals 2–49 years of age. This review summarizes clinical trial data in support of Q/LAIV.